{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-066933","form_type":"8-K","ticker":"SANA","cik":"0001770121","company_name":"Sana Biotechnology, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.642378+00:00","generated_at":"2026-05-22T05:04:35.236499+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sana reports Q1 net loss $49.4M, cash runway into 2026; new $119M ATM facility","bullets":["Net loss $49.4M ($0.21/share) vs $107.5M ($0.49/share) in Q1 2024; loss narrowed.","Cash $104.7M at Mar 31, 2025, down from $152.5M; non-GAAP cash burn $46.6M; runway into 2026.","Positive 12-week data for UP421 (HIP islet cells) in T1D: C-peptide production, immune evasion without immunosuppression.","Enrolling GLEAM (autoimmune) and VIVID (B-cell malignancies) trials; expect data in 2025.","New at-the-market (ATM) agreement with TD Cowen to sell up to $119M of common stock."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-066933","json":"https://secwatch.observer/filing/0000950170-25-066933.json","markdown":"https://secwatch.observer/filing/0000950170-25-066933.md","text":"https://secwatch.observer/filing/0000950170-25-066933.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770121/000095017025066933/0000950170-25-066933-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770121/000095017025066933/sana-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T05:04:35.236499+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}